We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 15, 2019

Pembrolizumab in Pediatric Patients With Advanced Melanoma or a PD-L1–Positive, Advanced, Relapsed, or Refractory Solid Tumor or Lymphoma

The Lancet Oncology


Additional Info

The Lancet Oncology
Pembrolizumab in Paediatric Patients With Advanced Melanoma or a PD-L1-Positive, Advanced, Relapsed, or Refractory Solid Tumour or Lymphoma (KEYNOTE-051): Interim Analysis of an Open-Label, Single-Arm, Phase 1-2 Trial
Lancet Oncol 2019 Dec 04;[EPub Ahead of Print], B Geoerger, HJ Kang, M Yalon-Oren, LV Marshall, C Vezina, A Pappo, TW Laetsch, AS Petrilli, M Ebinger, J Toporski, J Glade-Bender, W Nicholls, E Fox, SG DuBois, ME Macy, SL Cohn, K Pathiraja, SJ Diede, S Ebbinghaus, N Pinto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading